- EsoGuard/EsoCheck showed pretty slow growth in Q2 but momentum should improve as the company starts targeting consumers and PCPs directly and launches into Europe.
- Momentum for PAVM's pipeline products remains strong, and the company remains on track to get 3-4 products on the market by the end of 2022.
- In addition, subsidiary Veris Health is in talks with Microsoft which could lead to an eventual partnership.
- The valuation of the company remains low at $500mil despite the incredible momentum the company is showing and the clear disruptiveness of each of its products.
For further details see:
PAVmed: Long Term Investment Case Remains Despite Weak Q2